2026 is the inflection point where biotechnology stops being priced on promise and starts being priced on conversion. This isn’t a change in sentiment. It’s a change in operating constraints. Capital, regulators, and operators now press the same question: can you keep truth intact as a programme moves from concept to scale—through handoffs, pressure, and […]